MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income (loss)
$59,005K
Accrued expenses,
accrued collaboration...
$37,497K
Share-based compensation
expense
$37,003K
Accounts receivable, net
-$26,130K
Proceeds from issuance of
class a ordinary...
$40,753K
Other long-term
liabilities
$16,699K
Deferred income taxes
$13,002K
Non-cash lease expense
$3,666K
Depreciation and
amortization expense
$1,554K
Accounts payable
$142K
Net cash provided by
operating activities
$137,985K
Net cash provided by
financing activities
$33,023K
Canceled cashflow
$56,713K
Canceled cashflow
$7,730K
Net increase
(decrease) in cash and cash...
-$17,985K
Canceled cashflow
$171,008K
Proceeds from the
maturities of short-term...
$199,490K
Inventory
$28,531K
Prepaid expenses and
other current assets
$22,481K
Operating lease
liabilities
-$3,455K
Other long-term
assets
$1,210K
Net amortization
(accretion) of discounts on...
$916K
Net (gain) loss on
disposal of property and...
$120K
Payments in connection
with ordinary stock...
$7,730K
Net cash provided by
(used in) investing...
-$188,993K
Canceled cashflow
$199,490K
Purchases of short-term
investments
$386,915K
Purchases of property and
equipment
$1,568K
Back
Back
Cash Flow
source: myfinsight.com
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)